Screener
R&D at other companies
Other financials
Where this comes from
Reported directly by AbCellera Biologics Inc. in its filing.
Tagged under the XBRL concept us-gaap:ResearchAndDevelopmentExpense.
The source filing: AbCellera Biologics Inc.’s 10-Q, filed August 5, 2026.
- Filed
- Aug 5, 2026, 4:28 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001703057-26-000046
| Line item | Three months ended June 30, 2025 | Three months ended June 30, 2026 | Six months ended June 30, 2025 | Six months ended June 30, 2026 |
|---|---|---|---|---|
| Licensing and royalty revenue | 10,445 | 149 | 10,613 | 341 |
| Total revenue | 17,084 | 4,050 | 21,320 | 12,362 |
| Operating expenses: | ||||
| Research and development(1) | 39,213 | 45,987 | 81,711 | 92,649 |
| Sales, general, and administrative(1) | 21,986 | 13,850 | 41,054 | 26,185 |
| Depreciation and amortization | 5,470 | 6,990 | 10,801 | 13,828 |
| Total operating expenses | 66,669 | 66,827 | 133,566 | 132,662 |
| Loss from operations | (49,585) | (62,777) | (112,246) | (120,300) |
Item 1. Financial Statements (Unaudited)
FAQ
- What is AbCellera Biologics Inc.'s R&D?
- AbCellera Biologics Inc. (ABCL) reported R&D of $45.99M in Q2 2026.
- How has AbCellera Biologics Inc.'s R&D changed year-over-year?
- AbCellera Biologics Inc.'s R&D increased by 17.3% year-over-year, from $39.21M to $45.99M.
- What is the long-term trend for AbCellera Biologics Inc.'s R&D?
- Over 4 years (2021 to 2025), AbCellera Biologics Inc.'s R&D has grown at a 31.7% compound annual growth rate (CAGR), from $62.06M to $186.83M.
- What does R&D mean?
- Costs of research activities to discover new knowledge and development activities to translate research into new or improved products, services, processes, or technologies.
Ask your AI about AbCellera Biologics Inc.'s r&d.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude